PDE5抑制剂与cGMP信号通路相关疾病的研究进展

Advances in PDE5 inhibitors and diseases related to cGMP signaling pathway

磷酸二酯酶5(phosphodiesterase 5,PDE5)抑制剂通过阻断环磷酸鸟苷(cyclic guanosine monophosphate,cGMP)的分解,使包括一氧化氮(nitric oxide,NO)在内的血管舒张介质作用延长,从而导致阴茎和肺的血管舒张。PDE5主要在阴茎海绵体和肺血管中发现,所以其抑制剂的主要作用是延长阴茎勃起和降低肺血管压力。

Phosphodiesterase 5(PDE5)inhibitors,as drugs to dilate the corpora cavernosa of the penis through sexual stimulation,are used to treat erectile dysfunction,and are also approved for treating pulmonary arterial hypertension.With the in-depth studies,PDE5 inhibitors have been approved to treat a variety of diseases,such as cardiovascular diseases,Alzheimer disease,etc,but there is currently no overall review on clinical applications of PDE5 inhibitors.As known,the classic pathway of PDE5 inhibitors promotes cyclic guanosine monophosphate(cGMP)production.However,reports on downstream pathways regulated by cGMP are still unclear.This review summarized the research and clinical application progress of PDE5 inhibitors in different diseases,and the pharmacological bases of PDE5 inhibitors through cGMP signaling pathway are discussed.